Current status: Answer expected on 16 September 2026
To ask the Scottish Government, in light of the Scottish Medicines Consortium's decision in June 2026 to approve the use of semaglutide (Wegovy) to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, what discussions it has had with NHS boards regarding implementation.